Feb. 7, 2024—Corista announced it has received a class II medical device license from Health Canada for its DP3 platform, a web-based image-management system for digital pathology.
“We’ve been building a world-class solution for integrated pathology,” Corista CEO and cofounder Elizabeth Wingard said in a press release. “Attaining the class II medical device license from Canada is an important milestone in making this possible.”
The platform is CE marked under the European in vitro diagnostic medical devices regulation for use in routine diagnosis in the European Union and United Kingdom. The company announced in December a strategic partnership with Mortsel, Belgium-based Agfa HealthCare.